Michael Porter makes strategic investment in Avicanna Inc.
Zug, Switzerland ·
A personal investment by Altanova’s Founder and Executive Chairman, made in an investor capacity through PG Equity Group I, LLC.
Michael Porter, Founder and Executive Chairman of Altanova Pharma Group AG, has made a strategic investment in Avicanna Inc. (TSX: AVCN; OTCQX: AVCNF; FSE: 0NN) through PG Equity Group I, LLC.
Avicanna describes itself as a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products. Avicanna announced the closing of the strategic non-brokered private placement on 19 August 2026. Completion remains subject to the approval of the Toronto Stock Exchange.
The investment was made by Mr. Porter in a personal and investor capacity. Altanova Pharma Group AG is not a party to the placement and holds no securities of Avicanna Inc.
Full terms are set out in Avicanna’s news release of 19 August 2026.
About Altanova Pharma Group AG
Altanova Pharma Group AG is building a Swiss specialty pharmaceutical platform focused on differentiated therapies for chronic disease states. The Group oversees product strategy, quality, market access, medical governance and patient support across its therapeutic franchises.
Cultivation, where applicable, manufacturing, testing, batch release, logistics and dispensing are carried out by appropriately qualified and licensed partners. Cannexa is the Group’s first therapeutic franchise.
Media contact
For media enquiries, contact info@altanovapharma.com.